IGF2R — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2609674	0.74	8/20
SCHEMBL2609683	0.74	8/20
SCHEMBL2609678	0.62	8/20
SCHEMBL932254	0.61	8/20
SCHEMBL2609681	0.60	8/20
SCHEMBL670102	0.50	8/20
SCHEMBL2609676	0.69	7/20
SCHEMBL2609680	0.69	7/20
SCHEMBL2609671	0.67	7/20
SCHEMBL2609672	0.67	7/20
SCHEMBL932559	0.60	7/20
SCHEMBL941549	0.54	7/20
SCHEMBL705443	0.53	7/20
SCHEMBL1176004	0.51	7/20
SCHEMBL1527168	0.51	7/20
SCHEMBL3487136	0.51	7/20
SCHEMBL1250705	0.49	7/20
SCHEMBL1250707	0.49	7/20
SCHEMBL2527529	0.45	7/20
SCHEMBL118123	0.45	7/20

Clinical trials — most relevant to IGF2R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer	PHASE4	WITHDRAWN
Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma	PHASE3	COMPLETED
Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated	PHASE3	COMPLETED
GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)	PHASE2	COMPLETED
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer	PHASE2	COMPLETED
HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes	PHASE2	RECRUITING
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma	PHASE2	COMPLETED
MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer	PHASE2	COMPLETED
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors	PHASE1	WITHDRAWN
Acute Effect of HP-211 (Axulin) on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans	PHASE1	COMPLETED
First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers	PHASE1	COMPLETED
Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma	PHASE1	COMPLETED
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans	nan	UNKNOWN
Prognostic Value of Protein IMP3 Expression in Cervical Cancer	nan	COMPLETED
The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)	nan	COMPLETED
ERT in Pompe Disease: Elucidation of Molecular Structures Contributing to Enzyme Uptake and Immunoreactivity	nan	UNKNOWN
Role of LncRNA H19 in The Regulation of IGF-1R Expression	nan	COMPLETED
Klotho _ LRP-6 _ Gastric Adenocarcinoma	nan	UNKNOWN
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
Blood and Tissue Study of Patients in NIH Protocol 08-C-0800	nan	COMPLETED
Serum IGF-1 and IGF-1Ec in Malignancy Assessment	nan	ACTIVE_NOT_RECRUITING
Glycosylation in Patients With Galactosaemia	nan	COMPLETED
IRS Proteins and Trastuzumab Resistance	nan	COMPLETED
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
IGF and Other Neurotrophic Factors in Patients With Dementia	nan	COMPLETED
Study of Tissue, Blood, and Urine Samples From Patients With Advanced Prostate Cancer	nan	UNKNOWN
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
The Development of Human Immunologic Assays Specific to Folate Receptor Antigen	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a IGF2R binder may also engage these)

Protein	Name	Similarity
P08169	—	1.000	P08169 →
Q07113	—	1.000	Q07113 →
A1X150	—	0.986	A1X150 →
O54861	—	0.986	O54861 →
P0DSP1	—	0.985	P0DSP1 →
LOXL3	Lysyl oxidase homolog 3	0.984	landscape →
B4F6N6	—	0.984	B4F6N6 →
Q5RFQ6	—	0.984	Q5RFQ6 →
Q75ZY9	—	0.984	Q75ZY9 →
Q769I5	—	0.984	Q769I5 →
Q09YK0	—	0.984	Q09YK0 →
Q2QLA9	—	0.984	Q2QLA9 →
Q108U6	—	0.984	Q108U6 →
Q07DZ1	—	0.984	Q07DZ1 →
O18016	—	0.983	O18016 →
Q00PJ8	—	0.983	Q00PJ8 →
A0M8R7	—	0.983	A0M8R7 →
P48829	—	0.983	P48829 →
O73798	—	0.983	O73798 →
Q95209	—	0.983	Q95209 →
Q9Z175	—	0.983	Q9Z175 →
Q07E01	—	0.983	Q07E01 →
P97523	—	0.983	P97523 →
Q2IBC0	—	0.983	Q2IBC0 →
Q9EPR5	—	0.983	Q9EPR5 →
MET	Hepatocyte growth factor receptor	0.983	landscape →
Q66K08	—	0.982	Q66K08 →
Q9R097	—	0.982	Q9R097 →
A6H737	—	0.982	A6H737 →
Q92673	—	0.982	Q92673 →